Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 388

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 388
---
2025 and December 31, 2024 was as follows (in thousands):

|                                                  |     |     | June 30, 
     2025 |   |     |     | December 31, 
         2024 |   |
|:-------------------------------------------------|:----|:----|---------:|:--|:----|:----|-------------:|:--|
| Weighted average remaining lease term (in years) |     |     |      6.8 |   |     |     |          7.3 |   |
| Weighted average discount rate                   |     |     |      9.6 | % |     |     |          9.6 | % |

Other information related to leases for the six months ended June 30, 2025 and 2024 was as follows:

|                                                                        |     | Six Months Ended 
 June 30,         | 2025 |     |   | 2024 |
|:-----------------------------------------------------------------------|:----|:-----------------|-----:|:----|:--|-----:|
| Cash paid for amounts included in the measurement of lease liabilities |     | $                |  155 |     | $ |   61 |

As of June 30, 2025, future minimum commitments under operating leases were as follows (in thousands):

| Year Ending December 31,        
 2025 (remaining period)         |     | As of June 30, 2025 |    365 |   |
|:--------------------------------|:----|:--------------------|-------:|:--|
| 2026                            |     |                     |    730 |   |
| 2027                            |     |                     |    730 |   |
| 2028                            |     |                     |    764 |   |
| 2029                            |     |                     |    775 |   |
| Thereafter                      |     |                     |  1,744 |   |
| Total future lease payments     |     | $                   |  5,108 |   |
| Less: imputed interest          |     |                     | (1,347 | ) |
| Present value of lease payments |     | $                   |  3,761 |   |

F-49

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) 8. Redeemable Convertible Preferred Stock and Equity The Company’s Fourth Amended and Restated Certificate of Incorporation